{
  "docId": "019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "docSlug": "f1da613c1103b289ca26ebdf1a360ae4",
  "documentTitle": "Alkermes | Results Presentation Deck | 21 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 21,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes footnotes regarding non-GAAP reconciliation and royalty revenue impacts from Janssen license agreement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a86b-72ae-acf4-09eb2fd3a18a/5",
  "deckHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "deckJsonHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a.json",
  "deckAnchorHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.06,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Total Revenue",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "516bdc29-e4ea-4e68-a51b-e430259291a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.66,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Non-GAAP Net Income*",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae989296-2f7c-4ad3-b251-3dc5eecbb217",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.36,
        "y": 0.225
      },
      "kind": "chart",
      "text": "GAAP Net Loss",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd5e143b-7f91-415a-8fbd-05de7a28241a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "disclaimer",
      "text": "*Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. **In Q1'23, royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® (the “long-acting INVEGA products”) were $13.6 million, compared to $37.1 million in Q1'22. This decrease was driven primarily by Janssen’s partial termination of the license agreement related to sales of the long-acting INVEGA products in the U.S., effective Feb. 2, 2022. The Company and Janssen are engaged in ongoing arbitration proceedings related to, among other things, Janssen’s royalty and other obligations under the license agreement.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea06b250-a4fe-4bba-903e-c534b1e71604",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Q1 2023 Financial Results Summary**",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aa06336-3f38-47b7-b91b-e846375b77a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 4,
      "beatId": "0fef3e94-eaf0-4d79-bad2-b05ef8fd72cc",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck presents financial performance and commercial review, highlighting the need for updates.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}